Stevanato Group S.p.A. (STVN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Stevanato Group S.p.A. (STVN) trades at $19.34 with AI Score 45/100 (Grade C). Stevanato Group S. p. A. Market cap: $5.28B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026STVN stock analysis for 2026: Analysts have set a consensus price target of $24.75 for Stevanato Group S.p.A., suggesting 28.0% upside from the current price of $19.34. The AI MoonshotScore is 45/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
STVN: the 1 perspectives are evenly split.
How is this calculated? →Stevanato Group S.p.A. (STVN) Healthcare & Pipeline Overview
Stevanato Group S.p.A. delivers integrated solutions for the pharma and healthcare sectors, specializing in the design, production, and distribution of containment solutions, drug delivery systems, and medical devices. With a global presence and a focus on innovation, the company addresses the evolving needs of pharmaceutical manufacturers and healthcare providers.
What Is the Investment Thesis for STVN?
Stevanato Group S.p.A. presents a notable research candidate due to its strong market position in the pharmaceutical and healthcare industries. The company's integrated solutions approach, encompassing containment solutions, drug delivery systems, and medical devices, provides a competitive advantage. With a P/E ratio of 23.4 and a profit margin of 11.7%, Stevanato Group demonstrates solid financial performance. Growth catalysts include increasing demand for injectable drugs and biologics, as well as the expansion of its high-value solutions segment. The company's beta of 0.62 suggests lower volatility compared to the overall market. However, investors may want to evaluate potential risks such as competition and regulatory changes. Stevanato Group's focus on innovation and strategic partnerships positions it for long-term growth and value creation.
Based on FMP financials and quantitative analysis
STVN Key Highlights
- Market Cap of $5.28B reflects investor confidence in Stevanato Group's market position and growth potential.
- P/E ratio of 23.4 indicates a premium valuation, reflecting expectations for future earnings growth.
- Profit Margin of 11.7% demonstrates the company's ability to generate profits from its operations.
- Gross Margin of 29.0% highlights the efficiency of Stevanato Group's manufacturing and service processes.
- Dividend Yield of 0.34% provides a modest income stream for investors.
Who Are STVN's Competitors?
STVN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MASI Masimo Corporation | $179.95 | +0.00% | $9.42B | 55 |
| BTSG BrightSpring Health Services, Inc. | $70.56 | +2.22% | $13.85B | 90 |
| AXSM Axsome Therapeutics, Inc. | $240.85 | -1.42% | $12.39B | 31 |
| NUVL Nuvalent, Inc. | $123.73 | -0.00% | $9.10B | 57 |
| ATR AptarGroup, Inc. | $126.69 | -0.23% | $8.09B | 75 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are STVN's Key Strengths?
- Strong market position in the pharmaceutical and healthcare industries.
- Comprehensive suite of products and services.
- Established relationships with leading pharmaceutical companies.
- Global presence and distribution network.
What Are STVN's Weaknesses?
- Dependence on the pharmaceutical industry.
- Exposure to regulatory changes and compliance requirements.
- Competition from other medical device and equipment manufacturers.
- Potential for product liability claims.
What Could Drive STVN Stock Higher?
- New product launches in drug delivery systems, expected in Q4 2026.
- Increasing demand for injectable drugs and biologics.
- Expansion of high-value solutions segment.
- Potential acquisitions to expand product portfolio, expected by 2027.
What Are the Key Risks for STVN?
- Economic downturns and reduced healthcare spending.
- Technological obsolescence.
- Competition from other medical device and equipment manufacturers.
- Exposure to regulatory changes and compliance requirements.
- Product liability claims.
What Are the Growth Opportunities for STVN?
- Expansion of Drug Delivery Systems: Stevanato Group has a significant opportunity to expand its drug delivery systems business, particularly in the area of pen injectors and auto-injectors. The market for these devices is growing rapidly, driven by the increasing prevalence of chronic diseases such as diabetes and the growing demand for self-administered medications. The global drug delivery market is projected to reach $240 billion by 2026. Stevanato Group's expertise in engineering and manufacturing, combined with its strong relationships with pharmaceutical companies, positions it to capture a significant share of this market.
- Growth in Biologics and Injectable Drugs: The increasing demand for biologics and injectable drugs presents a significant growth opportunity for Stevanato Group. Biologics, which are complex molecules derived from living organisms, often require specialized containment and delivery solutions. Stevanato Group's expertise in glass manufacturing and its ability to provide high-quality vials, cartridges, and syringes make it a preferred supplier for pharmaceutical companies developing and manufacturing biologics. The global biologics market is expected to reach $490 billion by 2027, fueling demand for Stevanato Group's products.
- Geographic Expansion: Stevanato Group has the opportunity to expand its geographic footprint, particularly in emerging markets. These markets are experiencing rapid growth in healthcare spending and increasing demand for pharmaceutical products and services. By establishing a presence in these markets, Stevanato Group can tap into new customer bases and diversify its revenue streams. The company can leverage its existing relationships with multinational pharmaceutical companies to facilitate its expansion into emerging markets. Key target markets include China, India, and Southeast Asia.
- Strategic Partnerships and Acquisitions: Stevanato Group can pursue strategic partnerships and acquisitions to expand its product portfolio and enhance its capabilities. By partnering with or acquiring companies that offer complementary products or technologies, Stevanato Group can strengthen its position as a leading provider of integrated solutions for the pharmaceutical and healthcare industries. Potential targets include companies specializing in medical device design, engineering, or manufacturing. These partnerships can provide access to new markets and technologies, accelerating Stevanato Group's growth.
- Innovation in Containment Solutions: Stevanato Group can continue to innovate in the area of containment solutions, developing new and improved vials, cartridges, and syringes that meet the evolving needs of pharmaceutical companies. This includes developing solutions that are compatible with new drug formulations, such as biologics and cell therapies, as well as solutions that improve patient safety and convenience. By investing in research and development, Stevanato Group can maintain its competitive edge and capture a larger share of the containment solutions market. The company's focus on innovation will drive long-term growth and profitability.
What Opportunities Does STVN Have?
- Expansion into emerging markets.
- Growth in biologics and injectable drugs.
- Development of new drug delivery systems.
- Strategic partnerships and acquisitions.
What Threats Does STVN Face?
- Economic downturns and reduced healthcare spending.
- Technological obsolescence.
- Increased competition from low-cost manufacturers.
- Changes in government regulations and healthcare policies.
What Are STVN's Competitive Advantages?
- Strong relationships with leading pharmaceutical companies.
- Expertise in glass manufacturing and engineering.
- Integrated solutions approach providing a comprehensive suite of products and services.
- Proprietary technologies and intellectual property.
- Global presence and established distribution network.
What Does STVN Do?
Founded in 1949 and headquartered in Piombino Dese, Italy, Stevanato Group S.p.A. has evolved from a glass manufacturer into a leading provider of integrated solutions for the pharmaceutical and healthcare industries. The company's initial focus on glass tubing gradually expanded to include the design and production of glass containers for pharmaceutical use. Over the decades, Stevanato Group strategically broadened its capabilities through organic growth and acquisitions, incorporating engineering, plastic components, and advanced technologies into its portfolio. Today, Stevanato Group offers a comprehensive suite of products and services, including containment solutions such as vials, cartridges, and syringes; drug delivery systems like pen injectors and auto-injectors; medical devices; diagnostic solutions; and analytical services. The company also manufactures visual inspection machines, assembling and packaging machines, and glass forming machines. Stevanato Group operates globally, serving a diverse customer base of pharmaceutical companies, biotechnology firms, and healthcare providers. As a subsidiary of Stevanato Holding S.R.L., the company maintains a strong commitment to innovation, quality, and customer satisfaction, driving its continued growth and market leadership.
What Products and Services Does STVN Offer?
- Designs and manufactures glass containers for pharmaceutical use.
- Produces drug delivery systems, including pen injectors and auto-injectors.
- Offers medical devices and diagnostic solutions.
- Provides analytical services to pharmaceutical companies.
- Manufactures visual inspection machines for quality control.
- Produces assembling and packaging machines for pharmaceutical products.
- Develops and manufactures glass forming machines.
How Does STVN Make Money?
- Sells containment solutions (vials, cartridges, syringes) to pharmaceutical companies.
- Provides drug delivery systems for self-administered medications.
- Offers engineering and analytical services to support pharmaceutical manufacturing.
- Generates revenue from the sale of machinery used in pharmaceutical production.
What Industry Does STVN Operate In?
Stevanato Group operates within the medical instruments and supplies industry, which is experiencing steady growth driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements in healthcare. The market is competitive, with players like AptarGroup, Inc. (ATR) offering specialized solutions. Stevanato Group differentiates itself through its integrated solutions approach, providing a comprehensive suite of products and services to pharmaceutical and healthcare companies. The company's focus on high-value solutions, such as drug delivery systems and medical devices, aligns with the industry's trend towards more sophisticated and personalized healthcare solutions.
Who Are STVN's Key Customers?
- Pharmaceutical companies developing and manufacturing injectable drugs.
- Biotechnology firms producing biologics and biosimilars.
- Healthcare providers administering medications to patients.
- Diagnostic companies developing and manufacturing diagnostic tests.
F-Score 5/9Financial Health
Stevanato Group S.p.A.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.02 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 10%Key Financial Metrics
Return on equity for Stevanato Group S.p.A. stands at 9.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.5%, showing how much profit it generates from its asset base. STVN trades at a trailing price-to-earnings ratio of 23.39, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.1%, the inverse of the P/E and a quick read on earnings relative to price.
Stevanato Group S.p.A. (STVN) Valuation Context
Valued at $5.28B, STVN is classified as a mid-cap stock. Relative to its peer group, STVN's quantitative score of 45/100 is below the peer average of 62/100.
FY2026 estForward Outlook
Wall Street analysts project Stevanato Group S.p.A. revenue of about $1.28B for fiscal 2026, with EPS near $0.61. The estimate reflects 8 contributing analysts.
STVN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Stevanato's focus on drug delivery systems positions them well as pharma companies innovate new therapies.
- Insider activity suggests confidence in the company's long-term prospects, which is always encouraging.
- The community seems to recognize Stevanato's essential role in the healthcare supply chain, viewing it as relatively stable.
- Positive market perception around healthcare sector growth could benefit Stevanato, similar to how component suppliers benefited during the tech boom.
Bear Case
- Dependence on the pharmaceutical industry makes Stevanato vulnerable to regulatory changes and market shifts.
- Community discussions reveal concerns about increased competition in the drug delivery space.
- Recent market developments indicate potential supply chain disruptions that could impact Stevanato's production.
- Bearish sentiment suggests some investors are worried about Stevanato's ability to maintain its growth rate, reminiscent of concerns around some high-growth stocks during past economic slowdowns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
STVN Latest News
STVN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for STVN.
Price Targets
Consensus target: $24.75
STVN MoonshotScore
What does this score mean?
The MoonshotScore rates STVN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Stevanato Group S.p.A. Analysis
Leadership: Franco Stevanato
CEO
Franco Stevanato serves as the Chief Executive Officer of Stevanato Group S.p.A., leading a global workforce of 5521 employees. His career within the Stevanato Group has spanned several decades, during which he has held various leadership positions across different business units. He has been instrumental in driving the company's strategic growth initiatives, including expanding its presence in emerging markets and developing innovative solutions for the pharmaceutical and healthcare industries. His deep understanding of the company's operations and his commitment to innovation have been key to Stevanato Group's success.
Track Record: Under Franco Stevanato's leadership, Stevanato Group has achieved significant milestones, including expanding its product portfolio, increasing its market share, and enhancing its financial performance. He has overseen the successful integration of several acquisitions, strengthening the company's position as a leading provider of integrated solutions for the pharmaceutical and healthcare industries. His strategic vision and operational expertise have been instrumental in driving Stevanato Group's growth and profitability.
What Investors Ask About Stevanato Group S.p.A. (STVN) — Healthcare
What does Stevanato Group S.p.A. do?
Stevanato Group S.p.A. provides integrated solutions for the pharmaceutical and healthcare industries. The company designs, produces, and distributes a wide range of products and processes, including containment solutions such as vials, cartridges, and syringes; drug delivery systems like pen injectors and auto-injectors; medical devices; diagnostic solutions; and analytical services. Stevanato Group also manufactures visual inspection machines, assembling and packaging machines, and glass forming machines, serving a diverse customer base of pharmaceutical companies, biotechnology firms, and healthcare providers globally. The company's integrated approach and focus on innovation position it as a key player in the pharmaceutical supply chain.
What do analysts say about STVN stock?
Analyst consensus on Stevanato Group S.p.A. (STVN) reflects a generally positive outlook, driven by the company's strong market position and growth prospects in the pharmaceutical and healthcare industries. Key valuation metrics, such as the P/E ratio of 23.4, suggest a premium valuation, reflecting expectations for future earnings growth. Analysts highlight the company's increasing demand for injectable drugs and biologics, as well as the expansion of its high-value solutions segment, as key growth drivers. However, potential risks such as competition and regulatory changes are also considered. The consensus is that Stevanato Group is well-positioned for long-term growth, but investors should carefully evaluate the risks and opportunities before making investment decisions.
What are the main risks for STVN?
Stevanato Group S.p.A. faces several risks inherent to the medical instruments and supplies industry. Economic downturns and reduced healthcare spending could negatively impact demand for its products and services. Technological obsolescence poses a threat, requiring continuous innovation to maintain competitiveness. The company also faces competition from other medical device and equipment manufacturers, including low-cost manufacturers in emerging markets. Regulatory changes and compliance requirements could increase operating costs and delay product approvals. Additionally, Stevanato Group is exposed to potential product liability claims, which could result in significant financial losses. Effective risk management and mitigation strategies are crucial for the company's long-term success.
How does Stevanato Group S.p.A. navigate regulatory approval processes?
Stevanato Group S.p.A. navigates regulatory approval processes by adhering to stringent quality standards and maintaining close relationships with regulatory agencies such as the FDA and EMA. The company's products, including containment solutions and drug delivery systems, are subject to rigorous testing and validation to ensure compliance with applicable regulations. Stevanato Group's regulatory affairs team works closely with pharmaceutical companies to support their regulatory submissions and ensure that its products meet the required specifications. The company's track record of successful regulatory approvals demonstrates its commitment to quality and compliance. Ongoing monitoring of regulatory changes and proactive adaptation to new requirements are essential components of Stevanato Group's regulatory strategy.
How does Stevanato Group S.p.A. manage patent expiration risks?
Stevanato Group S.p.A. manages patent expiration risks through a combination of strategies, including continuous innovation, strategic partnerships, and diversification of its product portfolio. The company invests heavily in research and development to develop new and improved products and technologies, extending the lifecycle of its existing products and creating new revenue streams. Strategic partnerships with pharmaceutical companies and other technology providers enable Stevanato Group to access new markets and technologies, mitigating the impact of patent expirations. Diversification of its product portfolio across different therapeutic areas and delivery systems reduces the company's reliance on any single product or technology. These strategies enable Stevanato Group to mitigate the risks associated with patent expirations and maintain its competitive edge.
What are the key factors to evaluate for STVN?
Stevanato Group S.p.A. (STVN) holds an AI score of 45/100 (low). P/E: 23.4x vs the S&P 500's ~20-25x. Analysts target $24.75 (+28%). Not financial advice.
How frequently does STVN data refresh on this page?
STVN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven STVN's recent stock price performance?
Stevanato Group S.p.A. (STVN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in the pharmaceutical and healthcare industries. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and industry analysis.
- Future performance is subject to market conditions and company-specific factors.